De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
The purpose of this study is to find out whether radiotherapy to some of the lymph node areas can be safely omitted to decrease side effects without increasing the risk of the tumour coming back.
Oropharyngeal Cancer
RADIATION: Radiation|DRUG: Cisplatin
Event-free Survival, Time to first progress event or censoring in year, 5 years
Overall Survival, Time to death or censoring in year, 5 years|Local control, Percentage of patients with local control, 5 years|Regional Control, Percentage of patients with regional control, 5 years|Locoregional control, Percentage of patients with local and regional control, 5 years|Distant Metastasis-Free Survival, Time to distant metastasis or censoring in year, 5 years
The standard or usual treatment for this disease includes radiotherapy or radiotherapy combined with chemotherapy or antibody therapy.

These treatments are highly effective at curing most patients with HPV-related cancer of the oropharynx, but short and long-term side effects from treatment can be significant.